Neville Rodie & Shaw Inc. reduced its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.7% in the 4th quarter, HoldingsChannel reports. The firm owned 94,838 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Bristol-Myers Squibb were worth $5,812,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tradewinds Capital Management LLC raised its holdings in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Atlantic Trust LLC purchased a new position in Bristol-Myers Squibb during the second quarter worth about $111,000. Massey Quick Simon & CO. LLC raised its holdings in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Finally, Horan Capital Advisors LLC. purchased a new position in Bristol-Myers Squibb during the third quarter worth about $122,000. 69.70% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on the stock. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target for the company. in a report on Thursday. BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating for the company in a report on Tuesday, February 6th. Leerink Swann upped their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research report on Tuesday, February 6th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $65.58.

In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.70 on Friday. The company has a market cap of $102,620.00, a P/E ratio of 106.27, a PEG ratio of 1.95 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $51.52 and a 1 year high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 earnings per share. sell-side analysts predict that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. The ex-dividend date of this dividend was Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2018/02/11/neville-rodie-shaw-inc-has-5-81-million-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.